Sugi Predict

Sugi Predict / Compounds / SCHEMBL30924739

SCHEMBL30924739

SCHEMBL30924739

C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)CN)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)O

nearest known ligand 0.53

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ QRFPR Q96P65 3/20 0.53
▸ NPY5R Q15761 4/20 0.51
▸ NPY1R P25929 3/20 0.51
▸ NPY4R P50391 3/20 0.51
▸ TFPI P10646 1/20 0.49
▸ OPRL1 P41146 5/20 0.47
▸ IL23R Q5VWK5 3/20 0.47
▸ NPY2R P49146 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30924731 0.96 NPY4R (0.57) QRFPRNPY5RNPY1RNPY4RTFPI
SCHEMBL30924745 0.96 NPY4R (0.57) QRFPRNPY5RNPY1RNPY4RTFPI
SCHEMBL30924741 0.94 TFPI (0.57) NPY5RNPY1RNPY4RTFPIIL23R
SCHEMBL30924734 0.89 IL23R (0.57) QRFPRNPY5RNPY1RNPY4RTFPI
SCHEMBL29590389 0.88 QRFPR (0.58) QRFPRNPY5RNPY1RNPY4RTFPI
SCHEMBL29630348 0.88 QRFPR (0.53) QRFPRNPY5RNPY1RNPY4RNPY2R
SCHEMBL30481160 0.86 QRFPR (0.64) QRFPRNPY5RNPY1RNPY4RTFPI
SCHEMBL30924733 0.86 TFPI (0.56) QRFPRTFPIOPRL1IL23R
SCHEMBL30121028 0.86 QRFPR (0.56) QRFPRNPY5RNPY1RNPY4RNPY2R
SCHEMBL29590985 0.86 QRFPR (0.56) QRFPRNPY5RNPY1RNPY4RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026787-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION GLO PHARMA, INC. 2025-01-23 — — US disclosed
US-12162956-B2 Peptides and methods for reducing skin pigmentation GLO PHARMA, INC. (US) 2024-12-10 — — US disclosed
US-20240190917-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION GLO PHARMA, INC. 2024-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190917-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION MC1R, TYR, MC5R QRFPR 51/4885NPY5R 38/4885NPY1R 29/4885
US-12162956-B2 Peptides and methods for reducing skin pigmentation MC1R, TYR, MC5R QRFPR 51/4885NPY5R 38/4885NPY1R 29/4885
US-20250026787-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION MC1R, TYR, MC5R QRFPR 51/4885NPY5R 38/4885NPY1R 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback